Fabior is a drug owned by Mayne Pharma Llc. It is protected by 3 US drug patents filed from 2014 to 2020 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Feb 24, 2030. Details of Fabior's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US10568859 | Topical foam composition |
Feb, 2030
(4 years from now) | Active |
| US10688071 | Topical foam composition |
Feb, 2030
(4 years from now) | Active |
| US8808716 | Topical foam composition |
Feb, 2030
(4 years from now) | Active |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Fabior's patents.
Latest Legal Activities on Fabior's Patents
Given below is the list of recent legal activities going on the following patents of Fabior.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 4th Year, Large Entity | 15 Dec, 2023 | US10688071 |
| Surcharge for Late Payment, Large Entity | 15 Dec, 2023 | US10568859 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 15 Dec, 2023 | US10568859 |
| Maintenance Fee Reminder Mailed Critical | 16 Oct, 2023 | US10568859 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 11 Jan, 2022 | US8808716 |
| Post Issue Communication - Certificate of Correction | 27 May, 2021 | US10688071 |
| Email Notification Critical | 15 May, 2021 | US10688071 |
| Certificate of Correction Memo | 14 May, 2021 | US10688071 |
| Mail Certificate of Correction Memo | 14 May, 2021 | US10688071 |
| Email Notification Critical | 26 Apr, 2021 | US10688071 |
While patent expiration is one way of estimating the generic date of a drug, if a patent gets invalidated somehow, the generic of the drug may arrive early. Being aware of all relevant patents can help in avoiding legal pitfalls. Given below are details of the litigation history of Fabior and ongoing litigations to help you estimate the early arrival of Fabior generic.
Fabior's Litigations
Fabior been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Apr 28, 2014, against patent number US10568859. The petitioner , challenged the validity of this patent, with Leon LOUPENOK as the respondent. Click below to track the latest information on how companies are challenging Fabior's patents.
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
 | ||||
| US10688071 | February, 2015 |
Decision
(14 Jul, 2017) | Leon LOUPENOK | |
| US10568859 | April, 2014 |
Decision
(21 Dec, 2016) | Leon LOUPENOK | |
FDA has granted some exclusivities to Fabior. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Fabior, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Fabior.
Exclusivity Information
Fabior holds 1 exclusivities. All of its exclusivities have expired in 2015. Details of Fabior's exclusivity codes and their expiration dates are given below.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosage Form(NDF) | May 11, 2015 |
US patents provide insights into the exclusivity only within the United States, but Fabior is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Fabior's family patents as well as insights into ongoing legal events on those patents.
Fabior's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Fabior's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Feb 24, 2030 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Fabior Generic API suppliers:
Tazarotene is the generic name for the brand Fabior. 5 different companies have already filed for the generic of Fabior, with Cosette having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Fabior's generic
Alternative Brands for Fabior
Fabior which is used for treating acne vulgaris in patients 12 years of age or older., has several other brand drugs using the same active ingredient (Tazarotene). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
Apart from brand drugs containing the same ingredient, some generics have also been filed for Tazarotene, Fabior's active ingredient. Check the complete list of approved generic manufacturers for Fabior
About Fabior
Fabior is a drug owned by Mayne Pharma Llc. It is used for treating acne vulgaris in patients 12 years of age or older. Fabior uses Tazarotene as an active ingredient. Fabior was launched by Mayne Pharma in 2012.
Approval Date:
Fabior was approved by FDA for market use on 11 May, 2012.
Active Ingredient:
Fabior uses Tazarotene as the active ingredient. Check out other Drugs and Companies using Tazarotene ingredient
Treatment:
Fabior is used for treating acne vulgaris in patients 12 years of age or older.
Dosage:
Fabior is available in aerosol, foam form for topical use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 0.1% | AEROSOL, FOAM | Prescription | TOPICAL |